Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials

Chest

Volumn 145, Issue 6, 2014, Pages 1286-1297

  Dong, Yaa Hui ^a,b,c   Chang, Chia Hsuin ^a,c   Wu, Fe Lin Lin ^b,c   Shen, Li Jiuan ^b,c   Calverley, Peter M A ^d   Löfdahl, Claes Gor̈an ^e   Lai, Mei Shu ^a,c   Mahler, Donald A ^f,g  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; INFECTION RISK; INFLUENZA; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS;

ADMINISTRATION, INHALATION; GLUCOCORTICOIDS; HUMANS; INFLUENZA, HUMAN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUBERCULOSIS;

EID: 84901838031     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2137     Document Type: Article

References (66)

1. The global burden of disease: 2004 update. WHO website. http:// www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf. Accessed July 1, 2013.
2. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary diseases. Updated 2013. GOLD website. http:// www.goldcopd.org/uploads/users/files/GOLD-Report-2013-Feb20.pdf. Accessed July 28, 2013.
3. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975- 981.
4. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34(1):13-16.
5. Barnes NC. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J. 2007;16(3):149-154. (Pubitemid 46890606)
6. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162-166. (Pubitemid 47057852)
7. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med. 2010;104(2):246-252.
8. Calverley PMA, Anderson JA, Celli B, et al TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789. (Pubitemid 46294610)
9. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
10. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and metaanalysis. JAMA. 2008;300(20):2407-2416.
11. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219-229.
12. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68(12):1105-1113.
13. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143(4):1018-1024.
14. Lee CH, Lee MC, Shu CC, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis. 2013;13:194.
15. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med. 2011;183(5):675-678.
16. Shu CC, Wu HD, Yu MC, et al Taiwan Anti-Mycobacteria Investigation (TAMI) Group. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore). 2010;89(1):53-61.
17. Inghammar M, Ekbom A, Engström G, et al. COPD and the risk of tuberculosis-a population-based cohort study. PLoS ONE. 2010;5(4):e10138.
18. den Boon S, van Lill SWP, Borgdorff MW, et al. Association between smoking and tuberculosis infection: a population survey in a high tuberculosis incidence area. Thorax. 2005;60(7):555-557. (Pubitemid 40966208)
19. Horne DJ, Campo M, Ortiz JR, et al. Association between smoking and latent tuberculosis in the US population: an analysis of the National Health and Nutrition Examination Survey. PLoS ONE. 2012;7(11):e49050.
20. Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:57-71.
21. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week phase III trial. Int J Chron Obstruct Pulmon Dis. 2012;7:43-55.
22. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Updated March 2011. The Cochrane Collaboration website. http://handbook. cochrane.org. Accessed July 1, 2013.
23. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of metaanalytical methods with rare events. Stat Med. 2007;26(1):53-77. (Pubitemid 46099417)
24. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351-1375. (Pubitemid 38594143)
25. GlaxoSmithKline Clinical Study Register. A multicentre, randomised, double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD. SFCT01/SCO30002. GlaxoSmithKline Clinical Study Register website. http:// www.gsk-clinicalstudyregister.com/search?study-ids= SCO30002#rs. Accessed July 1, 2013.
26. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257-268.
27. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med. 2008;102(8):1099-1108.
28. GlaxoSmithKline Clinical Study Register. A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD). SCO100470. GlaxoSmithKline Clinical Study Register website. http:// www.gsk-clinicalstudyregister.com/search?study-ids=SCO100470#rs. Accessed July 1, 2013.
29. Zheng JP, Yang L, Wu YM, et al. The efficacy and safety of combination salmeterol (50 m g)/fluticasone propionate (500 μg) inhalation twice daily via Accuhaler in Chinese patients with COPD. Chest. 2007;132(6):1756-1763.
30. Calverley P, Pauwels R, Vestbo J, et al; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456. (Pubitemid 36173708)
31. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3):834-843. (Pubitemid 37123298)
32. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084-1091. (Pubitemid 35178706)
33. Aaron SD, Vandemheen KL, Fergusson D, et al Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545-555. (Pubitemid 351650535)
34. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6(5):320-329.
35. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(2):144-149. (Pubitemid 46115085)
36. Wouters EF, Postma DS, Fokkens B, et al COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60(6):480-487. (Pubitemid 40814047)
37. GlaxoSmithKline Clinical Study Register. A randomized, double-blind, parallel-group clinical trial evaluating the effect of the fluticasone propionate/salmeterol combination product 250/50mcg bid via DISKUS versus salmeterol 50mcg bid via DISKUS on bone mineral density in subjects with chronic obstructive pulmonary disease (COPD). SCO40041. GlaxoSmithKline Clinical Study Register website. http://www.gsk-clinicalstudyregister.com/search?study-ids= SCO40041#ps. Accessed July 1, 2013.
38. Reid DW, Wen Y, Johns DP, Williams TJ, Ward C, Walters EH. Bronchodilator reversibility, airway eosinophilia and antiinflammatory effects of inhaled fluticasone in COPD are not related. Respirology. 2008;13(6):799-809.
39. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166(10):1358-1363. (Pubitemid 35292702)
40. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297-1303. (Pubitemid 30245717)
41. Pauwels RA, Löfdahl CG, Laitinen LA, et al; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease . Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340(25):1948-1953. (Pubitemid 29288270)
42. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819- 1823. (Pubitemid 29251012)
43. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax. 1998;53(6):477-482. (Pubitemid 28308063)
44. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J; International COPD Study Group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet. 1998;351(9105):773-780. (Pubitemid 28112338)
45. GlaxoSmithKline Clinical Study Register. A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg bid, 500mcg bid, and placebo bid via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). FLTA3025. GlaxoSmithKline Clinical Study Register website. http:// www.gsk-clinicalstudyregister.com/search?study-ids=FLTA3025#rs. Accessed July 1, 2013.
46. Calverley PM, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858-1868.
47. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549-565.
48. Shaker SB, Dirksen A, Ulrik CS, et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD. 2009;6(2):104-111.
49. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metereddose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975-2000.
50. Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8:93.
51. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919. (Pubitemid 37540641)
52. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74-81. (Pubitemid 36150304)
53. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012;7:73-86.
54. Global strategy for asthma man agement and prevention. Updated 2012. GINA website. http:// www.ginasthma.org/local/uploads/files/GINA-Report-March13.pdf. Accessed July 1, 2013.
55. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92-100.
56. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy. 1999;54(7):691-699. (Pubitemid 29333609)
57. Schleimer RP. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc. 2004;1(3):222-230.
58. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007;176(5):454-459. (Pubitemid 47358099)
59. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84(3):304-315.
60. Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology. 2012;217(3):363-374.
61. Iovino F, Brouwer MC, van de Beek D, Molema G, Bijlsma JJ. Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease. Cell Microbiol. 2013;15(6):870-881.
62. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(suppl):S221-S247.
63. Hale BG, Albrecht RA, García-Sastre A. Innate immune evasion strategies of influenza viruses. Future Microbiol. 2010;5(1):23-41.
64. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009;374(9691):712-719.
65. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012;13:138.
66. Kesten S, Plautz M, Piquette CA, Habib MP, Niewoehner DE. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J. 2007;30(5):898-906. (Pubitemid 351194793)